日期 影响因子
日期:
2020 年 — 2026 年
2020
2021
2022
2023
2024
2025
2026
影响因子:
–

Safety and Efficacy of Lebrikizumab in Adolescent Patients with Moderate-to-Severe Atopic Dermatitis: A 52-Week, Open-Label, Phase 3 Study

Lebrikizumab治疗中重度特应性皮炎青少年患者的安全性和有效性：一项为期52周的开放标签3期研究

期刊:Dermatology and Therapy
影响因子:4.2
doi:10.1007/s13555-023-00942-y
Paller, Amy S; Flohr, Carsten; Eichenfield, Lawrence F; Irvine, Alan D; Weisman, Jamie; Soung, Jennifer; Pinto Correia, Ana; Natalie, Chitra R; Rodriguez Capriles, Claudia; Pierce, Evangeline; Reifeis, Sarah; Gontijo Lima, Renata; Armengol Tubau, Clara; Laquer, Vivian; Weidinger, Stephan
发表日期：2023
文献求助 收藏

Long-term Efficacy and Safety of Up to 108 Weeks of Ixekizumab in Pediatric Patients With Moderate to Severe Plaque Psoriasis: The IXORA-PEDS Randomized Clinical Trial

伊克珠单抗治疗中重度斑块状银屑病患儿长达 108 周的长期疗效和安全性：IXORA-PEDS 随机临床试验

期刊:Jama Dermatology
影响因子:11
doi:10.1001/jamadermatol.2022.0655
Paller, Amy S; Seyger, Marieke M B; Magariños, Gabriel A; Pinter, Andreas; Cather, Jennifer C; Rodriguez-Capriles, Claudia; Zhu, Danting; Somani, Najwa; Garrelts, Alyssa; Papp, Kim A
银屑病
发表日期：2022
文献求助 收藏

Population pharmacokinetic and exposure-efficacy analysis of ixekizumab in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)

ixekizumab 在中重度斑块状银屑病患儿中的群体药代动力学和暴露-疗效分析 (IXORA-PEDS)

期刊:British Journal of Clinical Pharmacology
影响因子:3
doi:10.1111/bcp.15034
Jackson, Kimberley; Chua, Laiyi; Velez de Mendizabal, Nieves; Pitou, Celine; Rodriguez Capriles, Claudia; Paller, Amy S; Lansang, Perla; Seyger, Marieke M B; Papp, Kim
银屑病
发表日期：2022
文献求助 收藏

Higher rates of skin clearance and efficacy in challenging body areas are associated with better health-related quality of life following ixekizumab maintenance treatment in pediatric patients with plaque psoriasis

在接受ixekizumab维持治疗的儿童斑块状银屑病患者中，皮肤清除率越高，难治部位的疗效越好，患者的健康相关生活质量也越高。

期刊:Pediatric Dermatology
影响因子:1.2
doi:10.1111/pde.14892
Hebert, Adelaide A; Bobonich, Margaret A; Rodriguez Capriles, Claudia; Gallo, Gaia; Li, Lingnan; Somani, Najwa; Ridenour, Terri; Wang, Yan; Edson-Heredia, Emily; Becker, Emily M
银屑病
发表日期：2022
文献求助 收藏

Efficacy and safety of ixekizumab in a phase III, randomized, double-blind, placebo-controlled study in paediatric patients with moderate-to-severe plaque psoriasis (IXORA-PEDS)

一项针对中重度斑块状银屑病患儿的 III 期随机、双盲、安慰剂对照研究评估了 ixekizumab 的疗效和安全性 (IXORA-PEDS)

期刊:British Journal of Dermatology
影响因子:9.6
doi:10.1111/bjd.19147
Paller, A S; Seyger, M M B; Alejandro Magariños, G; Bagel, J; Pinter, A; Cather, J; Keller, S; Rodriguez Capriles, C; Gontijo Lima, R; Gallo, G; Little, C A; Edson-Heredia, E; Li, L; Xu, W; Papp, K
银屑病
发表日期：2020
文献求助 收藏